Myocardial Infarction (MI) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive landscape in MI therapeutics.
- There will be 74,405,699 diagnosed prevalent cases of MI in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for MI.
- The marketed drugs space for MI consists of mostly small molecules that are 3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors, voltage-dependent L-type calcium channel blockers, and P2Y purinoceptor 12 antagonists.
- R&D activity within the MI space is significant, with 11 pipeline products in late-stage clinical development.
- Non-commercial sponsors dominate clinical trial development in MI, with the US, Germany, Canada, the Netherlands, and Spain emerging as the key countries for conducting trials in this disease space.
- Deals involving acquisitions and licensing agreements were the most common type of deals globally involving companies developing MI assets.
GlobalData’s Myocardial Infarction (MI) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the MI market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MI market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
- 1 Preface
- 1.1 Contents
- 1.2 Report Scope
- 1.3 List of Tables and Figures
- 1.4 Abbreviations
- 2 Key Findings
- 3 Disease Landscape
- 3.1 Disease Overview
- 3.2 Epidemiology Overview
- 3.3 Treatment Overview
- 4 Marketed Drugs Assessment
- 4.1 Leading Marketed Drugs
- 4.2 Overview by Mechanism of Action
- 4.3 Overview by Route of Administration
- 4.4 Marketed Drugs Profiles and Sales Forecasts
- 5 Pricing and Reimbursement Assessment
- 5.1 Annual Therapy Cost
- 5.2 Time to Pricing and Reimbursement
- 6 Pipeline Drugs Assessment
- 6.1 Phase III Pipeline Drugs
- 6.2 Overview by Development Stage
- 6.3 Overview by Molecule Type
- 6.4 Overview by Mechanism of Action
- 6.5 Overview by Route of Administration
- 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
- 6.7 Therapy Area and Indication-specific PTSR and LoA
- 7 Clinical Trials Assessment
- 7.1 Historical Overview
- 7.2 Overview by Phase
- 7.3 Overview by Status
- 7.4 Overview by Phase for Ongoing and Planned Trials
- 7.5 Trials with Virtual Components
- 7.6 Geographic Overview
- 7.7 Single-Country and Multinational Trials by Region
- 7.8 Top 20 Sponsors with Breakdown by Phase
- 7.9 Top 20 Sponsors with Breakdown by Status
- 7.10 Overview by Endpoint Status
- 7.11 Overview by Race and Ethnicity
- 7.12 Enrollment Data
- 7.13 Top 20 countries for Trial Sites
- 7.14 Top 20 Sites Globally
- 7.15 Feasibility Analysis - Geographic Overview
- 7.16 Feasibility Analysis - Benchmark Models
- 8 Deals Landscape
- 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
- 8.2 Recent Mergers, Acquisitions, and Strategic Alliances
- 9 Commercial Assessment
- 9.1 Key Market Players
- 10 Future Market Catalysts
- 11 Appendix
- 11.1 Methodology
- 11.2 Methodology - Sales Forecast
- 11.3 Methodology - Pricing and Reimbursement
- 11.4 Methodology - PTSR and LoA Analysis
- 11.5 About the Authors
- 11.6 Contact Us
- 11.7 Disclaimer
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook